“Shaping oncology innovation”. Our commitment.

Intellectual property

High value organization for oncology innovation

About us

Fully integrated platform for R&D value chain


Proved track record, high quality standards and fully compliant services.

Delivering innovative drugs and high quality CRO e CDMO services


The mission of NMS Group is to discover and develop new molecules and therapeutic strategies, contributing to shape the future of cancer care. Thanks to its unique fully integrated R&D chain, the Group is also committed in offering high quality pre-clinical, clinical and production services at a global level.
The vast scientific heritage of internal skills, technology and experience represents our excellence and the basis for achieving our goals with continuous commitment and enthusiasm.

NMS Group is the largest company in Italy committed in innovation and research and development in oncology.

About us

Our company is a high value organization covering the whole R&D process: from pre-clinical phase of research, to First-Time-In-Man of clinical phase, up to production and packaging of the finished drug. Nerviano Medical Sciences represents the innovative heart of the Group and make it an important and international reference in the field of personalized therapy. NMS Group also provides Research and Production services, addressed to local and international markets through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and Nerpharma, dealing with activities from formulation to production of the active principle.

Our numbers

About us

Active patents and
patent applications
Pre clinical
Overall worldwide collaborations with research & care Centers

Press Release & News >

Solna, 02.08.2018

Xspray Pharma and NerPharMa deliver clinical trial material to HyNap-Dasa study

Xspray Pharma reported that the first clinical trial material from NerPharMa S.r.l. has been delivered to the HyNap-Dasa clinical trial, the results of which are expected in Q3 2018. HyNap-Dasa is one of three product candidates that Xspray currently has in development. The company’s goal is to launch HyNap-Dasa on the US market in 2021.
Read more +
Nerviano, Italy, 01.06.2018

Nerviano Medical Sciences announces Collaboration and License Agreement with Merck to discover small molecule inhibitors of certain anticancer targets

Today Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, announced an agreement with Merck, a leading science and technology company, under which the two companies will collaborate on the discovery of small molecule inhibitors of certain molecular targets in the area of DNA damage repair.
Read more +